Pipeline overview

To beat incurable diseases, Diaccurate explores the new frontiers of oncology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing 3 proprietary therapeutics with novel mechanisms of action across several development programs: an optimized S6 Kinase inhibitor, highly selective oral  antitumoral agent that crosses the blood-brain barrier (DIACC3010), a sole-in-class KIF20A kinesin inhibitor, a novel oncology target, IV antitumoral agent with high selectivity towards cancer cells (DIACC2010), and an antibody drug conjugate using DIACC2010 as payload (DIACC2020).